<code id='6E8658635A'></code><style id='6E8658635A'></style>
    • <acronym id='6E8658635A'></acronym>
      <center id='6E8658635A'><center id='6E8658635A'><tfoot id='6E8658635A'></tfoot></center><abbr id='6E8658635A'><dir id='6E8658635A'><tfoot id='6E8658635A'></tfoot><noframes id='6E8658635A'>

    • <optgroup id='6E8658635A'><strike id='6E8658635A'><sup id='6E8658635A'></sup></strike><code id='6E8658635A'></code></optgroup>
        1. <b id='6E8658635A'><label id='6E8658635A'><select id='6E8658635A'><dt id='6E8658635A'><span id='6E8658635A'></span></dt></select></label></b><u id='6E8658635A'></u>
          <i id='6E8658635A'><strike id='6E8658635A'><tt id='6E8658635A'><pre id='6E8658635A'></pre></tt></strike></i>

          explore

          explore

          author:knowledge    Page View:6351
          JUUL store sign -- health coverage from STAT
          Stephanie Keith/Getty Images

          Documents released this week shed new light on an aggressive strategy from vape maker Juul to court Black leaders, including the Rev. Al Sharpton, to publicly support its e-cigarettes.

          Beginning in 2018, Juul executives, including the company’s CEO, discussed six- and seven-figure partnerships with civil rights organizations, one of which would have seen it send as much as $7 million to Sharpton’s group, according to internal emails and documents that were released this week as part of a legal settlement with the state of North Carolina.

          advertisement

          It’s not clear how much the company ultimately spent on the partnerships.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          After affirmative action ruling, medical educators look to 'holistic review'
          After affirmative action ruling, medical educators look to 'holistic review'

          AnnaMoneymaker/GettyImagesAfterhavingadaytoreadthroughtheSupremeCourt’sdecisiononaffirmativeaction,s

          read more
          Insmed lung disease drug hits target in key Phase 3 trial
          Insmed lung disease drug hits target in key Phase 3 trial

          AdobeAnexperimentaldrugfromInsmedIncorporatedsuccessfullyreducedlungproblemsamongpatientswithanairwa

          read more
          Cancer drug shortages should be causing more outrage
          Cancer drug shortages should be causing more outrage

          DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

          read more

          Merus drug and Keytruda shrank tumors in patients with head and neck cancer

          ThisimmunofluorescenceimageshowsTcells(ingreenandyellow)inthemicroenvironmentofaheadandnecksquamousc